Cerebral Vascular Smooth Muscle Cells

Cerebral Vascular Smooth Muscle Cells

Overview

Cerebral Vascular Smooth Muscle Cells

Overview

<table class="infobox infobox-cell">
<tr>
<th class="infobox-header" colspan="2">Cerebral Vascular Smooth Muscle Cells</th>
</tr>
<tr>
<td class="label">Taxonomy</td>
<td>ID</td>
</tr>
<tr>
<td class="label">Cell Ontology (CL)</td>
<td>[CL:0000359](https://www.ebi.ac.uk/ols4/ontologies/cl/classes/http%253A%252F%252Fpurl.obolibrary.org%252Fobo%252FCL_0000359)</td>
</tr>
<tr>
<td class="label">Database</td>
<td>ID</td>
</tr>
<tr>
<td class="label">Cell Ontology</td>
<td>[CL:0000359](https://www.ebi.ac.uk/ols4/ontologies/cl/classes/http%253A%252F%252Fpurl.obolibrary.org%252Fobo%252FCL_0000359)</td>
</tr>
<tr>
<td class="label">Protein</td>
<td>Function</td>
</tr>
<tr>
<td class="label">alpha-Smooth Muscle Actin (alphaSMA)</td>
<td>Contractile apparatus</td>
</tr>
<tr>
<td class="label">Smooth Muscle Myosin Heavy Chain (SM-MHC)</td>
<td>Force generation</td>
</tr>
<tr>
<td class="label">Calponin</td>
<td>Actin binding</td>
</tr>
<tr>
<td class="label">SM22alpha</td>
<td>Cytoskeletal organization</td>
</tr>
<tr>
<td class="label">Vimentin</td>
<td>Intermediate filament</td>
</tr>
<tr>
<td class="label">Desmin</td>
<td>Force transmission</td>
</tr>
<tr>
<td class="label">Drug Class</td>
<td>Mechanism</td>
</tr>
<tr>
<td class="label">Calcium channel blockers</td>
<td>Reduce Ca2+ influx</td>
</tr>
<tr>
<td class="label">ACE inhibitors/ARBs</td>
<td>Reduce Ang II</td>
</tr>
<tr>
<td class="label">Statins</td>
<td>Pleiotropic effects</td>
</tr>
<tr>
<td class="label">PDE5 inhibitors</td>
<td>Enhance cGMP</td>
</tr>
<tr>
<td class="label">Endothelin antagonists</td>
<td>Block ETA/ETB</td>
</tr>
</table>

Cerebral Vascular Smooth Muscle Cells plays an important role in the study of neurodegenerative diseases. This page provides comprehensive information about this topic, including its mechanisms, significance in disease processes, and therapeutic implications.

Cerebral vascular smooth muscle cells (cVSMCs) are specialized contractile cells that line the walls of cerebral arteries, arterioles, and small arteries within the brain. These cells play essential roles in regulating cerebral blood flow (CBF), maintaining the blood-brain barrier (BBB), and supporting brain homeostasis["@iadecola2004"][@rubin2007]. cVSMC dysfunction is increasingly recognized as a critical contributor to neurodegenerative processes in Alzheimer's disease (AD), Parkinson's disease (PD), vascular dementia, and other neurological disorders["@zlokovic2011"][@guajardocorrea2022].

<!-- taxonomy-enrichment -->

<!-- multi-taxonomy-enrichment -->

Multi-Taxonomy Classification

Taxonomy Database Cross-References

PanglaoDB Marker Cross-References

• Unknown (PanglaoDB):

External Database Links

• [Cell Ontology (CL:0000359)](https://www.ebi.ac.uk/ols4/ontologies/cl/classes/http%253A%252F%252Fpurl.obolibrary.org%252Fobo%252FCL_0000359)
• [OBO Foundry (CL:0000359)](http://purl.obolibrary.org/obo/CL_0000359)
• [Allen Brain Cell Atlas](https://portal.brain-map.org/atlases-and-data/bkp/abc-atlas)
• [CellxGene Census](https://cellxgene.cziscience.com/)
• [Human Cell Atlas](https://www.humancellatlas.org/)
• [PanglaoDB](https://panglaodb.se/)

Taxonomy & Classification

PanglaoDB Marker Cross-References

• Unknown (PanglaoDB):

External Database Links

• [Cell Ontology (CL:0000359)](https://www.ebi.ac.uk/ols4/ontologies/cl/classes/http%253A%252F%252Fpurl.obolibrary.org%252Fobo%252FCL_0000359)
• [OBO Foundry (CL:0000359)](http://purl.obolibrary.org/obo/CL_0000359)
• [Allen Brain Cell Atlas](https://portal.brain-map.org/atlases-and-data/bkp/abc-atlas)
• [CellxGene Census](https://cellxgene.cziscience.com/)
• [PanglaoDB](https://panglaodb.se/)

Introduction

The cerebral vasculature contains approximately 100 billion capillary endothelial cells supported by pericytes and surrounded by astrocyte end-feet, all of which work in concert with cVSMCs to maintain optimal brain function. Unlike peripheral vascular smooth muscle cells, cVSMCs exhibit unique phenotypic characteristics that reflect their specialized role in neural tissue perfusion[@iadecola2004]. These cells respond to neural activity through neurovascular coupling, ensuring that energy demands of active neurons are met through increased blood flow.

The importance of cVSMCs in neurodegeneration has become increasingly apparent through research linking vascular risk factors to cognitive decline and demonstrating that cerebrovascular pathology precedes or accompanies hallmark proteinopathies in AD and PD[@zlokovic2011][@guajardocorrea2022]. Understanding cVSMC biology provides crucial insights into disease mechanisms and identifies potential therapeutic targets.

Anatomy and Structure

Vascular Architecture

The cerebral arterial tree consists of distinct compartments, each with characteristic cVSMC populations[@iadecola2004][@rubin2007]:

Cellular Morphology

cVSMCs exhibit a distinctive contractile phenotype characterized by:

• Elongated, spindle-shaped cell bodies oriented circumferentially around vessels
• Dense myosin and actin filaments organized into contractile units
• Abundant rough endoplasmic reticulum for protein synthesis
• Surface caveolae containing receptors and ion channels
• Myoendothelial junctions connecting to endothelial cells[@rubin2007]

Key Structural Proteins

Molecular Biology

Ion Channels and Receptors

cVSMC function depends on precisely regulated ion channel expression[@rubin2007][@brozovich2016]:

Calcium signaling:

• L-type Cav1.2 channels: Primary voltage-gated calcium entry
• R-type Cav2.3 channels: Sustained calcium influx
• T-type Cav3.1/3.2 channels: Depolarization-induced calcium release
• IP3 receptors: Calcium release from internal stores
• BK and SK channels: Calcium-activated potassium efflux

• α1-adrenergic receptors: Sympathetic vasoconstriction
• Endothelin receptors (ETA/ETB): Potent vasoconstriction
• Angiotensin II receptors (AT1): Pressure regulation
• Serotonin receptors (5-HT2): Vasoconstriction
• Prostaglandin receptors: Vasodilation/constriction balance

• β-adrenergic receptors: Sympathetic vasodilation
• Nitric oxide receptors (sGC): cGMP-mediated relaxation
• Adenosine receptors (A2A/A2B): Metabolic vasodilation

Signaling Pathways

Key intracellular signaling cascades in cVSMCs:

Transcription Factors

• SRF (Serum Response Factor): Master regulator of contractile gene program
• Myocardin: Co-activator of SRF, drives differentiation
• KLF4: Phenotypic switching regulator
• Notch3: Critical for cVSMC development and CADASIL[@joutel1996]

Function in Cerebral Circulation

Autoregulation

cVSMCs maintain constant CBF across a wide range of systemic blood pressures (approximately 60-150 mmHg mean arterial pressure)[@iadecola2004][@rubin2007]:

• Myogenic response: Intrinsic vessel response to pressure changes
• Rapid adaptation: Seconds to minutes timescale
• Impairment: Leads to hyper-/hypoperfusion injuries
• Age-related decline: Autoregulatory range narrows

Neurovascular Coupling

Activity-dependent blood flow regulation requires cVSMC coordination[@iadecola2004][@zlokovic2011]:

Blood-Brain Barrier Support

cVSMCs contribute to BBB integrity through[@rubin2007]:

• Structural support: Maintaining vessel wall integrity
• Pericyte recruitment: Secretion of PDGF-BB for pericyte function
• Tight junction regulation: Supporting endothelial barrier properties
• Transport regulation: Controlling paracellular and transcellular passage

Role in Neurodegenerative Diseases

cVSMC dysfunction is central to the [neurovascular unit](/mechanisms/neurovascular-coupling) damage seen in [Alzheimer's disease](/diseases/alzheimers-disease), [Parkinson's disease](/diseases/parkinsons-disease), and [vascular dementia](/diseases/vascular-dementia), interacting with [amyloid-beta](/proteins/amyloid-beta) and [tau](/proteins/tau) pathology.

Alzheimer's Disease (AD)

cVSMC dysfunction represents a major contributor to vascular cognitive impairment and interacts with AD pathology[@zlokovic2011][@kelley2020]:

Mechanisms:

• Cerebral amyloid angiopathy (CAA): Aβ deposition in cVSMC membranes leads to:
• Loss of cVSMC viability and function
• Impaired vasodilation and autoregulation
• Increased risk of hemorrhagic stroke
• Reduced clearance of Aβ from brain interstitial fluid[@kelley2020]
• Vessel rarefaction: Progressive loss of cerebral vessels reduces CBF
• White matter hypoperfusion: Contributing to white matter lesions
• Neurovascular uncoupling: Impaired functional hyperemia

• Reduced cerebral blood flow, particularly in posterior regions
• White matter hyperintensities on MRI
• Mixed dementia (vascular + AD pathology)
• Increased sensitivity to blood pressure fluctuations

• Aβ immunization and anti-aggregates
• Vasculoprotective agents
• Angiotensin receptor blockers (AT1)
• PDE inhibitors to enhance cGMP signaling[@kelley2020]

Parkinson's Disease (PD) and Lewy Body Dementia

cVSMC involvement in [PD](/diseases/parkinsons-disease) and [Lewy body dementia](/diseases/lewy-body-dementia) involves [alpha-synuclein](/proteins/alpha-synuclein) pathology and [neuroinflammation](/mechanisms/neuroinflammation), with parallels to [cerebral amyloid angiopathy](/diseases/cerebral-amyloid-angiopathy) in AD.

Mechanisms:

• α-Synuclein pathology: Lewy bodies in cVSMCs affect function
• Cerebrovascular dysfunction: Precedes motor symptoms in some cases
• Blood-brain barrier disruption: Increased permeability
• Reduced vasodilatory capacity: Endothelial and cVSMC dysfunction

• Reduced cerebral blood flow in basal ganglia
• Orthostatic hypotension due to autonomic dysfunction
• Increased stroke risk
• Cognitive impairment from vascular contributions

Vascular Dementia

cVSMC dysfunction is central to vascular cognitive impairment[@gorelick2011]:

• Small vessel disease: cVSMC degeneration in penetrating arterioles
• White matter lesions: Hypoperfusion-driven demyelination
• Lacunar infarcts: cVSMC failure and vessel occlusion
• Binswanger's disease: Subcortical leukoaraiosis

CADASIL

Notch3 mutations cause hereditary cVSMC degeneration[@joutel1996][@chabriat2009]:

• Notch3 extracellular domain accumulation in cVSMC membranes
• Progressive vessel wall thickening and lumen narrowing
• Characteristic MRI changes: White matter lesions, lacunes
• Clinical features: Migraine, strokes, cognitive decline

Therapeutic Approaches

Current Pharmacological Strategies

Emerging Therapies

• Gene therapy: AAV-delivered neurotrophic factors (BDNF, NGF)
• Stem cell therapy: cVSMC progenitors for vessel repair
• Antisense oligonucleotides: Targeting pathological gene expression
• BBB-penetrant antioxidants: Reducing oxidative stress[@kelley2020]

Overview

Cerebral Vascular Smooth Muscle Cells plays an important role in the study of neurodegenerative diseases. This page provides comprehensive information about this topic, including its mechanisms, significance in disease processes, and therapeutic implications.

Background

The study of Cerebral Vascular Smooth Muscle Cells has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.

Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.

External Links

• [Brain Cell Atlas](https://www.braincellinfo.org)
• [Allen Brain Map](https://www.brain-map.org)
• [NIH - Cell Types Database](https://www.ninds.nih.gov)

References

brozovich2016, Mechanisms of vascular smooth muscle contraction (2016) (2016)
chabriat2009, CADASIL (2009) (2009)
faucheux2003, Alpha-synuclein in cerebral vessels (2003) (2003)
gorelick2011, Vascular cognitive impairment (2011) (2011)
guajardocorrea2022, Cerebrovascular dysfunction in PD (2022) (2022)
iadecola2004, Iadecola C, Neurovascular regulation in the normal brain and in AD (2004) (2004)
joutel1996, Notch3 mutations in CADASIL (1996) (1996)
kelley2020, Kelley RE, Cerebral amyloid angiopathy in AD (2020) (2020)
rubin2007, Rubin LL, The blood-brain barrier (2007) (2007)
zlokovic2011, Zlokovic BV, Neurovascular pathways to neurodegeneration in AD (2011) (2011)